| Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection S Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ... New England Journal of Medicine 378 (4), 354-369, 2018 | 483 | 2018 |
| Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label … X Forns, SS Lee, J Valdes, S Lens, R Ghalib, H Aguilar, F Felizarta, ... The Lancet infectious diseases 17 (10), 1062-1068, 2017 | 417 | 2017 |
| Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis PY Kwo, F Poordad, A Asatryan, S Wang, DL Wyles, T Hassanein, ... Journal of hepatology 67 (2), 263-271, 2017 | 347 | 2017 |
| Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis T Asselah, KV Kowdley, N Zadeikis, S Wang, T Hassanein, Y Horsmans, ... Clinical Gastroenterology and Hepatology 16 (3), 417-426, 2018 | 266 | 2018 |
| Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment F Poordad, F Felizarta, A Asatryan, MS Sulkowski, RW Reindollar, ... Hepatology 66 (2), 389-397, 2017 | 215 | 2017 |
| Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial D Wyles, F Poordad, S Wang, L Alric, F Felizarta, PY Kwo, B Maliakkal, ... Hepatology 67 (2), 514-523, 2018 | 180 | 2018 |
| Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure F Poordad, S Pol, A Asatryan, M Buti, D Shaw, C Hézode, F Felizarta, ... Hepatology 67 (4), 1253-1260, 2018 | 165 | 2018 |
| Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial RS Brown Jr, M Buti, L Rodrigues, V Chulanov, WL Chuang, H Aguilar, ... Journal of hepatology 72 (3), 441-449, 2020 | 163 | 2020 |
| High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis E Gane, F Poordad, S Wang, A Asatryan, PY Kwo, J Lalezari, DL Wyles, ... Gastroenterology 151 (4), 651-659. e1, 2016 | 126 | 2016 |
| Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study MM Jonas, RH Squires, SM Rhee, CW Lin, K Bessho, ... Hepatology 71 (2), 456-462, 2020 | 102 | 2020 |
| Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana … A Kurup, CW Lin, DJ Murry, L Dobrolecki, D Estes, CT Yiannoutsos, ... Annals of oncology 17 (1), 97-103, 2006 | 79 | 2006 |
| Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection EJ Lawitz, WD O'Riordan, A Asatryan, BL Freilich, TD Box, JS Overcash, ... Antimicrobial agents and chemotherapy 60 (3), 1546-1555, 2016 | 62 | 2016 |
| ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis GR Foster, E Gane, A Asatryan, T Asselah, PJ Ruane, S Pol, F Poordad, ... J Hepatol 66 (1), S33, 2017 | 60 | 2017 |
| Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infections and compensated liver disease E Gane, F Poordad, N Zadeikis, J Valdes, CW Lin, W Liu, A Asatryan, ... Clinical Infectious Diseases 69 (10), 1657-1664, 2019 | 36 | 2019 |
| ENDURANCE-1: efficacy and safety of 8-versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection S Zeuzem, JJ Feld, S Wang, M Bourliere, H Wedemeyer, EJ Gane, ... Hepatology 64, 132A-133A, 2016 | 36 | 2016 |
| High efficacy of ABT-493 and ABT-530 in HCV genotype 1-infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I Study F Poordad, SC Gordon, A Asatryan, F Felizarta, RW Reindollar, C Landis, ... In vitro 1, 3, 2016 | 36 | 2016 |
| 100% SVR4 with ABT-493 and ABT-530 with or without ribavirin in treatment-naive HCV genotype 3-infected patients with cirrhosis PY Kwo, DL Wyles, S Wang, F Poordad, E Gane, B Maliakkal, ... Journal of hepatology 2 (64), S208, 2016 | 28 | 2016 |
| Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first‐in‐human study CW Lin, S Dutta, A Asatryan, H Wang, J Clifton, A Campbell, W Liu Clinical Pharmacology in Drug Development 7 (1), 44-52, 2018 | 27 | 2018 |
| Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study CW Lin, S Dutta, A Asatryan, YL Chiu, H Wang, J Clifton II, A Campbell, ... Journal of Pharmaceutical Sciences 106 (2), 645-651, 2017 | 27 | 2017 |
| Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection S Flamm, KR Reddy, N Zadeikis, T Hassanein, BR Bacon, A Maieron, ... Clinical gastroenterology and hepatology 17 (3), 527-535. e6, 2019 | 26 | 2019 |
